Free Trial
OTCMKTS:BNXTF

BioNxt Solutions Q3 2025 Earnings Report

BioNxt Solutions logo
$0.27 0.00 (0.00%)
As of 10/2/2026

BioNxt Solutions EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BioNxt Solutions Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioNxt Solutions Announcement Details

Quarter
Q3 2025
Time
During Market Hours
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

BioNxt Solutions Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
BioNxt Solutions Inc.
See More BioNxt Solutions Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioNxt Solutions? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioNxt Solutions and other key companies, straight to your email.

About BioNxt Solutions

BioNxt Solutions (OTCMKTS:BNXTF) is a biotechnology company focused on developing pharmaceutical and drug-delivery technologies. Its work centers on alternative dosage forms designed to improve the administration, absorption, and convenience of medicines, including oral dissolvable and sublingual films, transdermal systems, and other novel delivery platforms.

The company’s development activities have included pharmaceutical products and delivery systems targeting areas such as neurological disorders and other medical conditions. BioNxt has also pursued the development and commercialization of proprietary formulations and related technologies through partnerships and operating activities in North America and Europe, including Germany.

BioNxt Solutions was formerly known as XPhyto Therapeutics Corp. and adopted its current name as it focused more directly on pharmaceutical development and drug-delivery solutions. The company is headquartered in Vancouver, British Columbia, and its leadership has included Chief Executive Officer Hugh Rogers.

View BioNxt Solutions Profile